Monday 03 November 2025
Internal Reference Number: FOI_8629
Date Request Received: 06/05/2025 00:00:00
Date Request Replied To: 04/08/2025 00:00:00
This response was sent via: By Email
Request Summary: Biologics Rheumatology
Request Category: Companies
| Question Number 1: Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Baricitinib [Olumiant] • Bimekizumab [Bimzelx] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Filgotinib [Jyseleca] • Golimumab [Simponi] • Guselkumab [Tremfya] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Rituximab [MabThera] • Rituximab Biosimilars • Sarilumab [Kevzara] • Secukinumab [Cosentyx] • Tocilizumab [Ro Actemra] • Tocilizumab Biosimilars • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara] • Ustekinumab Biosimilar | |
| Answer To Question 1: • Abatacept [Orencia] - 44 • Adalimumab [Humira] - 28 • Adalimumab Biosimilars - 402 • Apremilast [Otezla] - 5 • Baricitinib [Olumiant] - 25 • Bimekizumab [Bimzelx] - 11 • Certolizumab [Cimzia] - 35 • Etanercept [Enbrel] - 9 • Etanercept Biosimilars - 134 • Filgotinib [Jyseleca] - 24 • Golimumab [Simponi] - 9 • Guselkumab [Tremfya] - 18 • Infliximab [Remicade] - 5 • Infliximab Biosimilars – 2 + 5 • Ixekizumab [Taltz] - <5 • Risankizumab [Skyrizi] - 0 • Rituximab [MabThera] - 0 • Rituximab Biosimilars - 0 • Sarilumab [Kevzara] - <5 • Secukinumab [Cosentyx] - 11 • Tocilizumab [Ro Actemra] - 33 • Tocilizumab Biosimilars - 0 • Tofacitinib [Xeljanz] - 18 • Upadacitinib [Rinvoq] - 63 • Ustekinumab [Stelara] - 0 • Ustekinumab Biosimilar - <5 | |
| Question Number 2: Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs. • Adalimumab [Humira] • Adalimumab Biosimilars • Bimekizumab [Bimzelx] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Golimumab [Simponi] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Secukinumab [Cosentyx] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] | |
| Answer To Question 2: • Adalimumab [Humira] 0 • Adalimumab Biosimilars 22 • Bimekizumab [Bimzelx] 0 • Certolizumab [Cimzia] <5 • Etanercept [Enbrel] <5 • Etanercept Biosimilars <5 • Golimumab [Simponi] <5 • Infliximab [Remicade] 0 • Infliximab Biosimilars 13 • Ixekizumab [Taltz] <5 • Secukinumab [Cosentyx] 0 • Tofacitinib [Xeljanz] 0 • Upadacitinib [Rinvoq] <5 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
